This article will address the topic of Tivantinib, which has captured the attention of a wide spectrum of people today. Various aspects related to Tivantinib will be explored, from its origin and evolution to its relevance in contemporary society. Its implications in different areas will also be examined, as well as the opinions and positions of experts and specialists in the field. Through an in-depth analysis, we will seek to provide a comprehensive and enriching vision of Tivantinib, with the aim of offering readers a broader and more detailed understanding of this fascinating topic.
![]() | |
![]() | |
Clinical data | |
---|---|
Other names | ARQ197; ARQ-197 |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.231.891 |
Chemical and physical data | |
Formula | C23H19N3O2 |
Molar mass | 369.424 g·mol−1 |
3D model (JSmol) | |
| |
|
Tivantinib (ARQ197; by Arqule, Inc.) is an experimental small molecule anti-cancer drug. It is a bisindolylmaleimide that binds to the dephosphorylated MET kinase in vitro. (MET is a growth factor receptor.) Tivantinib is being tested clinically as a highly selective MET inhibitor. However, the mechanism of action of tivantinib is still unclear.[citation needed]
Tivantinib displays cytotoxic activity via molecular mechanisms that are independent from its ability to bind MET, notably tubulin binding, which likely underlies tivantinib cytotoxicity.
Possible applications include non-small-cell lung carcinoma, hepatocellular carcinoma, and oesophageal cancer.
In 2017, it was announced that a phase III clinical trial for advanced hepatocellular carcinoma had failed to meet the primary endpoint.